T Cell Kit for mRNA
Rethink Cell Therapy with Lipid Nanoparticles.
The GenVoy-ILM T Cell Kit for mRNA is an LNP reagent mix. It is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr® Spark™ instrument and cartridges.
This kit enables researchers to establish a clinically-relevant and scalable method for ex vivo gene delivery to advance the development of T cell therapies. It can be used at various stages of cell therapy research and development from discovery to preclinical across the NxGen™ microfluidics instrument platform.
GREATER PROPORTION OF ENGINEERED CELLS
HIGH CELL VIABILITY
Nucleic acids delivered using the GenVoy-ILM T Cell Kit for mRNA are potent without causing cytotoxicity, resulting in highly viable cells that can be assayed in vitro and in vivo.
TUNABLE BIOLOGICAL OUTCOMES
Delivering mRNA into activated human primary T cells using the GenVoy-ILM T Cell Kit for mRNA leads to a higher proportion of engineered T cells, making it a more potent gene delivery method than electroporation.
Engineering human primary T cells using the GenVoy-ILM T Cell Kit for mRNA results in highly uniform protein expression across the treated cell population.
Activated human primary T cells remain highly viable after ex vivo gene delivery using the GenVoy-ILM T Cell Kit for mRNA.
Achieve an ideal balance between transfection efficiency, protein expression, and cell viability in a dose-dependent manner.
CAR T cells engineered using the GenVoy-ILM T Cell Kit for mRNA effectively kill CD19+ tumor cells in a dose-dependent manner.
Easily Integrated into Standard T Cell Culture Protocols
A simpler workflow combined with minimal T cell manipulation enable higher cell viability.